Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-08-19

FDA Approved: LABETALOL HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Labetalol Hydrochloride from Hikma Pharmaceuticals USA Inc., approving changes to the product's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Labetalol Hydrochloride (Labetalol hydrochloride)

Snippet

SUPPL AP for LABETALOL HYDROCHLORIDE (LABETALOL HYDROCHLORIDE)